Xeloda Growth Due To Off-Label Adjuvant Colorectal Cancer Use, Roche Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The increase in Xeloda prescribing is also “partly due to some change in the reimbursement patterns,” Pharma Strategic Marketing Head Sabbah says. U.S. sales for the first quarter were up 74% to approximately $51 mil.